Géraldine Gebhart

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 341 citations · Full text

Breast Oncology, Oncology, Engineering +13

¹⁸F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Géraldine Gebhart, Cristina Gámez‐Cenzano, Eileen Holmes et al. · Journal of Nuclear Medicine · 2013 · 157 citations · Full text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial

Hatem A. Azim, Françoise Rothé, Claudia Aura et al. · The Breast · 2013 · 40 citations · Full text